Business Context and Reporting Period
This Form 8-K Current Report was filed by Zentalis Pharmaceuticals, Inc. on February 13, 2023. The filing discloses the appointment of Iris Roth, Ph.D., as Chief Operating Officer, effective February 13, 2023. Dr. Roth brings over 20 years of experience in drug development and commercialization, most recently serving as Vice President, Medicine Development Leader at GlaxoSmithKline.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment terms.
- Base Salary: $434,476 annually.
- Target Bonus: 40% of annual base salary.
- Stock Options: 297,500 shares with a four-year vesting schedule (25% cliff, then monthly).
- Restricted Stock Units (RSUs): 52,500 shares vesting in four equal annual installments.
Material Changes
The primary material change is the addition of Dr. Roth to the executive leadership team. No financial performance changes or operational shifts are reported in this document.
Guidance, Outlook, and Compensation Terms
The filing details severance provisions under Dr. Roth's employment agreement:
- Termination without Cause/Good Reason: Entitles Dr. Roth to 9 months of base salary, a prorated target bonus, and 9 months of COBRA premiums.
- Change in Control Provisions: If termination occurs within 18 months of a change in control, severance increases to 12 months of base salary and COBRA, with a full target bonus payment. All stock awards vest immediately upon termination following a change in control.
- Termination for Cause: Limited to earned but unpaid salary and accrued time off.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the exercise price of the 297,500 stock options based on the Nasdaq closing price on the grant date.
- Review the Company's 2020 Incentive Award Plan to understand the broader equity pool impact.
- Assess the potential dilution impact of the 350,000 total equity units (options and RSUs) granted.